Approximation to the cost of pharmacological treatment of rheumatoid arthritis in Spain;Aproximación al coste del tratamiento farmacológico en la artritis reumatoide en España

Anales de Medicina Interna

Volumn 20, Issue 3, 2003, Pages 114-121

  Mera Varela, A ^a   Blanco Rodriguez, J ^a   Caamano Freire M ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Arthritis; Cost; Economic; Pharmacological; Rheumatoid

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEMOGRAPHY; DISEASE DURATION; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RADIOLOGY; REGISTER; REMISSION; RHEUMATOID ARTHRITIS; RURAL AREA; SPAIN; STOMACH PROTECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; SPAIN;

EID: 0037363819     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Tornero Molina J, Vidal Fuentes J: Impacto social y económico de las enfermedades reumáticas. La discapacidad laboral. Rev Esp Reumatol 1999; 26: 357-66.
2. Estudio EPISER: Prevalencia e impacto de las enfermedades reumáticas en la población adulta española. Ed. MSD y Sociedad Española de Reumatología. Madrid, 2001.
3. Edmonds JP, Scott DL, Furst DE, Brooks DP, Paulus HE: Antirheumatic drugs: a proposed new classification. Arthritis Rheum 1993; 20: 546-7.
4. Spencer-Green G: Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis 2000; 59 (Supl. 1): 46-9.
5. Furst DE, Breedveld FC, Burmester GR, Crofford JJ, Emery P, Feldmann M, et al: Updated consensus statement on tumour necrosis factor blocking agentes for the treatment of rhematoid artritis. Ann Rheum Dis 2000; 59 (Supl. 1): 1-2.
6. van Zeben D, Breedveld FC: Pronostic factors in rheumatoid artritis. J Rheumatol 1996; 43 (Supl. 44): 31-3.
7. Mutru O, Laakso M, Koota K. Ten years mortality and causes of death in patients with rheumatoid artritis. BMJ 1985; 290: 1797-9.
8. Vanderbroucke JP, Hazevoer HM, Cats A: Survival and cause of death in rheumatoid artritis: a 25 years prospective follow-up. J Rheum 1984; 11: 448-53.
9. Arnett FC, Edworthy SM, Bloch DA et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
10. Peter JB, Reyes HR: Use and interpretation of test in Rheumatology. Ed. Specialty Laboratories, 1996. p. 114-6.
11. Steinbrocker O, Traeger GH, Batterman RC: Therapeutic criteria in Rheumatoid Artritis. JAMA 1949; 140: 659-62.
12. Hochberg M, Chang RW, Dwosh I, et al: The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498-502.
13. Pinals RS, Masi AT, Larsen RA, et al: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 1308-15.
14. Heluwa A, Bombardier C, Goldsmith CH, Mendions B, Smythe HA. Costs-effectiveness of impatient and intensive outpatient treatment of rheumatoid arthritis. Arthritis Rheum 1989; 32: 1505-14.
15. Goossens ME, Rutten-van-Molken PMH, Vlaeyen JWS, van der Linden SMJ. The cost diary: a method to measure direct and indirect costs in cost-effectiviness research. J Clin Epidemiol 2000; 53: 688-95.
16. Cooper NJ: Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000; 39: 28-33.
17. Yelin E: The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996; 23: 47-51.
18. Singh G, Ramey D, Terry R. Direct costs in medical care in rheumatoid arthritis: patterns and role of Rheumatology care. Arthritis Rheum 1997; 39 (Supl.) 9: 837A.
19. Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK, Bulpitt KJ: Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol 2000; 27: 1156-63.
20. Wong JB, Ramey DR, Singh G: Long term morbidity, mortality and economics of Rheumatoid Arthritis. Arthritis Rheum 2001; 44: 2746-49.
21. Hernández García, C, González Alvaro I, Villaverde García V, Vargas Castrillón E: Estudio sobre el manejo de la artritis reumatoide. Editorial SER, 2001.
22. Cooper NJ, Mugford M, Scott DGI, Barret EM, Symmons DPM: Secondary health service care and second line drug costs of early inflammatory polyarthritis in Norfolk, UK. J Rheumatol 2000; 27: 2115-22.
23. Gabriel SE, Coyle D, Moreland LW: A clinical and economic review of disease-modifyng antirheumatic drugs. Pharmacoeconomics 2001; 19: 715-28.
24. Nuijten MJ, Engelfriet P, Duijin K, Bruijn G, Wierz D, Koopmanschap M. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001; 19: 1051-64.
25. Choi HK, Seeger JD, Kuntz KM: A cost-effectiviness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rhem 2000; 43: 2316-27.
26. Tugwell P: Combination therapy in rheumatoid artritis: Metaanalysis. J Rheumatol 1996; 23 (Supl. 44): 43-6.
27. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S, et al: Cost-effectiviness and cost-utility of combination therapy in early rheumatoid arthritis:randomised comparison of combined step-down prednisolona, methotrexate and sulphasalazine with sulphasalazine alone (COBRA TRIAL GROUP). Br J Rheumatol 1998; 37: 1102-09.
28. Raskin JB: Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 1999; 106 (5B): 3S-12S.
29. Maetzel A, Bosi Feraz M, Bombardier C. The cost-effectiviness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antinflammatory drugs. Arthritis Rheum 1998; 41: 16-25.
30. Yeomans N, Wilson I, Langstrom G, Hawkey C, Naesdal J, Walan A, Wiklund I: Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol 2001; 30: 328-34.
31. Raskin JB: Gastrointestinal effects of non-steroidal anti-inflammatory therapy. Am J Med 1999; 106: 3S-12S.
32. Rehman Q, Lane NE: Bone losss. Therapeutic approaches for preventing bone loss in inflammatory arthritis. Arthritis Res 2001; 3: 221-7.
33. Miller PD: Biphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. Osteoporos Int 2001; 12 (Supl. 3): S3-S10.
34. Dickens C, Creed F: The burden of depression in patients with rheumatoid arthritis. Rheumatology 2001; 40: 1327-30.
35. Pardell H, Tresserras R, Armario P, Hernández del Rey R: Pharmacoeconomic considerations in the menagement of hypertension. Drugs 2000; (Supl. 2): 13-20.
36. Kvalvik AG, Jones MA, Symmons DPM: Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. scand J Rheumatol 2000; 29: 29-37.
37. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silvershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998. p. 1837-1847.
38. Albers JM, Kuper HH, van Riel PL, Prevoo ML, van t'Hof MA, van Gestel AM, et al: Socio-economic consequences of rheumatoid artritis in the first years of the disease. Rheumatology 1999; 38: 423-30.
39. van Jaarsveld CHM, Jacobs JWG, Schrijvers JP, et al: Direct costs of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol 1998; 37: 837-47.
40. Anderson JJ, Wells G, Verhooven AC, Felson DT: Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis rheum 2000; 43: 22-9.
41. ERAS Study Group: Socioeconomic deprivation and rheumatoid disease: what lessons for the health service? ERAS Study Group.Early Rheumatoid Arthritis Study. Ann Rheum Dis 2000; 59: 794-9.
42. Álvaro-Gracia JM, andreu sánchez JL, Batlle Gualda E y miembros del comité de Expertos de la SER: Consenso de la Sociedad de Reumatología sobre la terapia con inhibidores de TNF y otros fármacos inductores de remisión en la artristis reumatoide. Rev Esp Reumatol 2000; 27: 352-54.
43. Bombardier C, Maetzel A: Pharmacoeconomic evaluation of new treatments: efficacy versus effectiviness studies?. Ann Rheum Dis 1999; 58 (Supl. 1): 182-85.
44. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guideliness: Guideliness for the menagement of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328-46.
45. Misischia RJ, Moreland LW: Use of biological agents in the treatment of Rheumatoid arthritis. JCOM 2001; 8: 54-60.
46. Mitchell JM, Burkhauser RV, Pincus T. The importance of age, education and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. Arthritis Rheum 1988; 31: 348-57.
47. Young A, Dixey J, Kulinskaya E, Cox N, Davies P, Devlin J, et al: Which patients stop working because of rheumatoid arthritis?. Results of five years follow up in 732 patients from de early RA study (ERAS). Ann Rheum Dis 2002; 61: 335-40.
48. Sokka T, Pincus T: Markers for work disability in rheumatoid arthritis. J Rheumatol 2001; 28: 1718-22.
49. Holte HH, Tambs K, Bjerkedal T. Becoming a disability pensioner with rheumatoid arthritis in Norway 1871-1990. J Rheumatol 2001; 28: 54-61.
50. De Roos AJ, Callahan LF: Differences by sex in correlates of work status in rheumatoid arthritis patients. Arthritis Care Res 1999; 12: 381-91.
51. Gasto real por Capítulos. Distribucion por programas 2000. http:/www.sergas.es/gal/organización/datosinterés 13-1.htm.
52. Producto Interior Bruto regional de España frente a las medias europeas. http://www.comadrid.es/iestadis/npib9598.htm.